Both in Pharmaceuticals
Ocular Therapeutix vs Innoviva
Over the past year OCUL returned −34.5% and INVA returned +17.1%; their daily moves had a correlation of 0.10.
OCUL −34.5% INVA +17.1%Growth of $1, one year, split-adjusted
| Metric | OCUL | INVA |
|---|---|---|
| Price | $7.14 | $21.26 |
| Market cap | $1.57B | $1.54B |
| Today | +4.69% | +1.58% |
| 1 month | −2.7% | +2.1% |
| 6 months | −26.5% | −5.6% |
| Year to date | −41.2% | +6.4% |
| 1 year | −37.4% | +17.4% |
| Revenue growth (YoY) | +0.1% | +19.3% |
| Gross margin | 85.1% | 81.3% |
| Net margin | −584.5% | −69.8% |
| P/E (TTM) | — | 4.3× |
| Price / sales | 30.1× | 3.5× |
| Net cash | $525.8M | $319.0M |
| Dividend yield | — | — |
| Volatility (60d) | 75.4% | 21.1% |
| Short % of float | 15.1% | 10.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).